US20020013331A1 - Methods and compositions for treating pain of the mucous membrane - Google Patents
Methods and compositions for treating pain of the mucous membrane Download PDFInfo
- Publication number
- US20020013331A1 US20020013331A1 US09/888,466 US88846601A US2002013331A1 US 20020013331 A1 US20020013331 A1 US 20020013331A1 US 88846601 A US88846601 A US 88846601A US 2002013331 A1 US2002013331 A1 US 2002013331A1
- Authority
- US
- United States
- Prior art keywords
- composition
- percent
- pharmaceutically
- mucoadhesive
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OUSRMLOKXBEGCT-UHFFFAOYSA-N C.C.C.C.[H]OCCOCC(C)OCCO Chemical compound C.C.C.C.[H]OCCOCC(C)OCCO OUSRMLOKXBEGCT-UHFFFAOYSA-N 0.000 description 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to methods and compositions for treating the pain associated with mucosal damage, such as inflamation, abrasions, ulcerations, lesions, incisions, and trauma.
- mucous membrane refers to the moist linings of the buccal cavity, nasal cavity, gastrointestinal tract, respiratory tract, conjunctiva, vagina, colon, urinary bladder, and urethra (Forstner et al., 1973 J. Cell. Sci. 12:585; Peppas et al., 1985 J Control Release 2:257; Lehr et al., 1992 J. Control. Release 18:249; Spiro, 1970 Ann. Rev. Biochem. 39:599; Lebat-Robert et al., 1979 Path. Biol. 24:241).
- the normally smooth, moist, and pink buccal mucosa is very sensitive and inflamation or ulceration (oral mucositis) causes severe pain.
- Dental surgery such as root canal and tooth extraction can also severely damage the buccal mucosa causing severe pain.
- oral mucositis and dental surgery can induce secondary conditions, such as weight loss and dehydration from reluctance to eat or drink, infection (bacterial, fungal, and viral), fever, nausea, and diarrhea.
- Oral mucositis has a variety of causes, for example, bacterial infections, such as streptococci; viral infections, such as herpes simplex virus; fungal infections; side effects of systemic diseases; vitamin deficiency; iron deficiency; cheek biting; mouth breathing; jagged teeth; orthodontic appliances; ill-fitting dentures; excessive use of alcohol or tobacco; thermally-hot foods; spicy foods; and as a side effect of medication.
- Severely-painful oral mucositis is a symptom endured by almost all chemotherapy patients. Mucositis symptoms peak 7 to 10 days following chemotherapy, and gradually recede over the following two weeks.
- Topical application of local anesthetics can provide some relief of oral-mucositis and dental-surgery pain but absorption through the mucous membranes occurs rapidly, and pharmaceuticals applied to the mucous membrane for their local effect sometimes cause systemic toxicity ( Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th ed. J. G. Harman and L. E. Limird Eds., McGraw-Hill New York 1996 p. 8) especially with the higher doses required for adequate pain relief. Systemic absorption is even more likely when the mucous membrane is ulcerated or inflamed.
- anesthetic compositions for mucositis e.g., 2 percent lidocaine oral rinse or 5% lidocaine ointment
- systemic toxicity limits the dosage and so adequate pain relief is difficult to achieve.
- Other less toxic pain relieving compositions such as rinses comprising hydrogen peroxide and sodium bicarbonate are less effective at reducing pain.
- An additional problem with oral rinses is, that following application, the action of swallowing and saliva reduces the concentration of active agent on the affected area, thus oral rinses comprising local anesthetics have a low duration of activity.
- the invention provides compositions and methods that provide long-lasting local anesthesia and effective pain relief.
- the compositions of the invention can be topically applied to the affected area, for example, via a dose-metered applicator adapted for spraying or adapted for use with a cannula.
- the compositions of the invention provide a powerful local-anesthetizing effect, in spite of low anesthetic concentration.
- the compositions of the invention provide significant pain relief with low systemic absorption and, therefore, low systemic toxicity.
- the compositions of the invention in addition to the ability to remain on the affected area for extended periods, hydrate and soothe.
- compositions of the invention can be topically applied directly to the affected area to alleviate pain in a subject on any area of a subject's body.
- compositions of the invention are useful for topical application to a subject's mucous membrane, to induce a long-lasting local-anesthetic effect, thereby relieving pain from mucositis, such as mucosal inflamation, abrasions, ulcerations, and lesions, without significant systemic absorption.
- compositions of the invention are useful for topical application to the site of dental surgery, such as root-canal or tooth-extraction surgery, to induce a long-lasting local-anesthetic effect, thereby relieving the surgical pain, without significant systemic absorption.
- the invention relates to compositions comprising a mucoadhesive, a local anesthetic or a pharmaceutically-acceptable salt thereof, and an opioid or a pharmaceutically-acceptable salt thereof.
- the compositions contain water and are sterile.
- the compositions of the invention further comprise a chelating agent and a preservative.
- the invention in another embodiment, relates to a container adapted for topical application and containing a pharmaceutically-acceptable composition comprising a mucoadhesive, a local anesthetic or a pharmaceutically-acceptable salt thereof, and an opioid or a pharmaceutically-acceptable salt thereof.
- the container is adapted for dose-metered application, such as a dose-metered pump for use with a spray applicator or cannula.
- the invention relates to a method of inducing local anesthesia in a subject's mucosal membrane by topically applying a pharmaceutically-acceptable composition comprising a local anesthetic or a pharmaceutically-acceptable salt thereof and an opioid or a pharmaceutically-acceptable salt thereof to the subject's mucosal membrane.
- a pharmaceutically-acceptable composition comprising a local anesthetic or a pharmaceutically-acceptable salt thereof and an opioid or a pharmaceutically-acceptable salt thereof to the subject's mucosal membrane.
- the composition is applied to an area within the subject's buccal or nasal cavity.
- the composition further comprises a mucoadhesive.
- the invention relates to a method of inducing local anesthesia in a subject by topically applying a composition comprising a mucoadhesive, a local anesthetic or a pharmaceutically-acceptable salt thereof, and an opioid or a pharmaceutically-acceptable salt thereof to a subject.
- a composition comprising a mucoadhesive, a local anesthetic or a pharmaceutically-acceptable salt thereof, and an opioid or a pharmaceutically-acceptable salt thereof to a subject.
- the composition is applied to a mucosal surface of the subject, for example, an area within the subject's buccal or nasal cavity.
- phrases “pharmaceutically-acceptable salt(s),” as used herein includes but is not limited to salts of acidic or basic groups that may be present in compounds used in the present compositions.
- Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
- the acids that may be used to prepare pharmaceutically-acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including, but not limited to, sulfuric, citric, maleic, acetic, oxalic, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfon
- Compounds included in the present compositions that include an amino moiety may form pharmaceutically-acceptable salts with various amino acids, in addition to the acids mentioned above.
- Compounds, included in the present compositions, that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
- Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
- opioid means all agonists and antagonists of opioid receptors, such as mu ( ⁇ ), kappa ( ⁇ ), and delta ( ⁇ ) opioid receptors and subtypes thereof.
- opioid receptors and subtypes see Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th ed. J. G. Harman and L. E. Limird Eds., McGraw-Hill New York:1996 pp. 521-555, incorporated herein by reference.
- the opioid can be any opioid receptor agonist or antagonist known or to be developed.
- Preferred opioids interact with the ⁇ -opioid receptor, the ⁇ -opioid receptor, or both.
- the opioid is an opioid-receptor agonist.
- Suitable opioids for use with the invention include, but are not limited to, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, benzitramide, nor-binaltorphimine, bremazocine, buprenorphine, butorphanol, clonitazene, codeine, CTOP, DAMGO, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydrocodeine enol acetate, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, diprenorphine, DPDPE, eptazocine, ethoheptazine, ethylketocyclazocine, ethyhnethylthiambutene, etonitazene, et
- Examples of peptide opioids include, but are not limited to, Tyr-Gly-Gly-Phe-Leu ([Leu 5 ]enkephalin), Tyr-Gly-Gly-Phe-Met ([Met 5 ]enkephalin), Tyr-Gly-Gly-Phe-Leu-Arg -Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln (DynorphinA), Tyr-Gly-Gly-Phe-Leu -Arg-Arg-Gln-Phe-Lys-Val-Val-Thr (Dynorphin B), Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr -Pro-Lys ( ⁇ -Neoendorphin), Tyr-Gly-Gly-Phe-Leu-Arg-Lsy-Tyr-Pro ( ⁇ -Neoendorphin), Tyr-Gly-Gly-Phe-Leu
- Preferred opioids include morphine, loperamide and loperamide derivatives such as those disclosed in U.S. Pat. Nos. 5,763,445; 5,981,513; 5,869,521; 5,744,458; 5,760,023; 5,798,093; 5,849,762; 5,811,078; 6,004,964; 5,962,477; 5,688,955; 5,888,494; 5,646,151; and 5,667,773 (all of which patents are incorporated by reference herein), or pharmaceutically-acceptable salts thereof, or mixtures thereof.
- the most preferred opioid is morphine or a pharmaceutically-acceptable salt thereof.
- local anesthetic means any drug that provides local numbness or analgesia or any drug that provides a regional blockage of nociceptive pathways (afferent and/or efferent) and that is not an agonist or an antagonist of an opioid receptors.
- the local anesthetic can be any local anesthetic known or to be developed.
- Examples of local anesthetics suitable for use with the invention include: ambucaine, amolanone, amylcaine, benoxinate, benzocaine, betoxycaine, biphenamine, bupivacaine, butacaine, butamben, butanilicaine, butethamine, butoxycaine, carticaine, chloroprocaine, cocaethylene, cocaine, cyclomethycaine, dibucaine, dimethisoquin, dimethocaine, diperodon, dyclonine, ecogonidine, ecogonine, euprocin, fenalcomine, formocaine, hexylcaine, hydroxyteteracaine, isobutyl ⁇ -aminobenzoate, leucinocaine, levoxadrol, lidocaine, mepivacaine, meprylcaine, metabutoxycaine, methyl chloride, myrtecaine, naepaine, octacaine, orthocaine,
- the amide and ester type local anesthetics are preferred.
- Amide type local anesthetics are characterized by an amide functionality, while ester type local anesthetics contain an ester functionality.
- Preferred amide type local anesthetics include lidocaine, bupivacaine, prilocaine, mepivacaine, etidocaine, ropivacaine, dibucaine, and pharmaceutically-acceptable salts thereof and mixtures thereof.
- Preferred ester type local anesthetics include tetracaine, procaine, benzocaine, chloroprocaine, and pharmaceutically-acceptable salts thereof and mixtures thereof. The most preferred local anesthetic is lidocaine.
- local anesthetic also encompasses drugs not traditionally associated with local anesthetic properties but which have a local-anesthetic effect, for example, non-narcotic analgesics, such as, acetylsalicylic acid, ketoprofen, piroxicam, diclofenac, indomethacin, ketorolac, Vioxx®, and Celebrex®.
- non-narcotic analgesics such as, acetylsalicylic acid, ketoprofen, piroxicam, diclofenac, indomethacin, ketorolac, Vioxx®, and Celebrex®.
- local anesthetics with different pharmacodynamics and pharmacokinetics may be combined in a composition of the invention.
- a preferred combination of local anesthetics is lidocaine and prilocaine and another preferred combination is lidocaine and tetracaine.
- the term “local delivery” of a therapeutic means topical application of the therapeutic to a subject, whereafter a therapeutically-effective amount of the therapeutic is absorbed in the immediate application area, preferably, without significant absorption into the blood stream.
- a “therapeutically-effective amount” of the compositions of the invention means the amount required to induce a local-anesthetic effect or numbness sufficient to ameliorate pain induced by ulceration, inflamation, or lesions of the buccal or nasal membrane or other mucous membranes or the pain associated with mucosal trauma, such as dental surgery.
- the active agents of the composition are not absorbed systemically.
- the term “subject” means any animal, preferably a mammal, more preferably a human.
- mucoadhesive means a natural or synthetic substance, e.g., gels, pastes, macromolecules, polymers, and oligomers, or mixtures thereof, that can adhere to a subject's mucous membrane for a period of time sufficient to locally deliver a therapeutically-effective amount of a composition of the invention to a subject. Adhesion of mucoadhesives to the mucous membrane occurs primarily via secondary chemical bonds, such as hydrogen bonding and Van der Waal forces (Tabor et al., 1977 J Colloid Interface Sci. 58:2 and Good 1977 J Colloid Interface Sci. 59:398). Mucoadhesive substances often form viscous aqueous solutions.
- the composition itself does not need to be mucoadhesive, as long as it can form a mucoadhesive gel upon on the contact with the mucous membrane.
- gellan gum itself is a very weak mucoadhesive.
- gellan gum can interact with the ions in the mucous membrane and form an adhesive gel layer.
- mucoadhesives possess binding properties that may be distinguished from non-mucoadhesives by comparing the degree of adhesion to a mucosal surface.
- a potential mucoadhesive with a control emulsion of comparable viscosity prepared without mucoadhesive properties, e.g., a starch solution.
- the emulsion prepared with the mucoadhesive will bind to the mucosal surface more strongly than will the control emulsion, preferably at least 25% greater mucosal binding than the control emulsion, more preferably at least 50% greater, still more preferably at least 100% greater mucosal binding.
- Either mechanical binding to mucous membrane per se or the degree of biological effect of a drug delivered may be used as a measurement parameter for mucoadhesion. This test may be used to distinguish preferred mucoadhesives.
- Substances can be screened for their ability to be used as mucoadhesives for local delivery of compositions of the invention according to the methodology described in Smart et aL, 1982 J Pharm. Pharmacol. 34:70P and Smart et al., 1984 J Pharm. Pharmacol. 36:295, which methodology comprises estimating values of adhesive strength between the substance and the mucous membrane.
- the mucoadhesive is water soluble, such that at least 1% by weight of the mucoadhesive is soluble in water at 25° C.
- the mucoadhesive will exhibit non-Newtonian fluid properties, i.e., the viscosity decreases with increasing shear forces.
- the viscosity of the composition can be modulated by altering the shear forces present when the composition is applied to a surface.
- a composition with non-Newtonian fluid properties becomes less viscous when shaken or atomized, then, upon standing, returns to its original viscosity.
- mucoadhesives for use in the present invention include, but are not limited to, pectin, alginic acid, chitosan, hyaluronic acid, polysorbates, such as polysorbate-20, -21, -40, -60, -61, -65, -80, -81, -85; poly(ethyleneglycol), such as PEG-7, -14, -16, -18, -55, -90, -100, -135, -180, -4, -240, -6, -8, -9, -10, -12, -20, or -32; oligosaccharides and polysaccharides, such as gellan, carrageenan, xanthan gum, gum Arabic, and dextran; cellulose esters and cellulose ethers; modified cellulose polymers, such as carboxymethylcellulose, hydroxyethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl ethylcellulose;
- poly(ethylene oxide) for example, condensation products of poly(ethylene oxide) with fatty acids, fatty alcohols, fatty amides, polyhydric alcohols; polyether compounds, such as poly(methyl vinyl ether), polyoxypropylene of less than 10 repeating units; polyether compounds, such as block copolymers of ethylene oxide and propylene oxide; mixtures of block copolymers of ethylene oxide and propylene oxide with other excipients, for example, pluronic lethicin organogel (see 1997 International Journal of Pharmaceutical Compounding 1:71); poly(vinyl alcohol); polyacrylamide; hydrolyzed polyacrylamide; poly(vinyl pyrrolidone); poly(methacrylic acid); poly(acrylic acid) or cosslinked polyacrylic acid, such as carbomer, i.e., a homopolymer of acrylic acid crosslinked with either an allyl ether of pentaerythritol, an allyl ether of sucrose, or an
- x is an integer having an average value within the range of from about 2 to about 128
- y is an integer having an average value within the range of from about 14 to about 80
- z is an integer having an average value within the range of from about 2 to about 128.
- x and y are about equal.
- More preferred block copolymers of ethylene oxide and propylene oxide, falling within the genus represented by formula I, are shown in Table 1 below.
- the most preferred mucoadhesive for use with the invention is poloxamer 407.
- the block copolymers of ethylene oxide and propylene oxide sold under the trade name Pluronic are commercially available, e.g., BASF (Washington, N.J.).
- the block copolymers of ethylene oxide and propylene oxide sold under the trade name Calgene are commercially available, e.g., Calgene Chemical, Inc. Skokie, Ill.
- compositions of the invention when administered to a subject, are sterile.
- Suitable preservatives include, but are not limited to, quaternary ammonium compounds, such as benzalkonium chloride, benzethonium chloride, cetrimide, dequalinium chloride, and cetylpyridinium chloride; mercurial agents, such as phenylmercuric nitrate, phenylmercuric acetate, and thimerosal; alcoholic agents, for example, chlorobutanol, phenylethyl alcohol, and benzyl alcohol; antibacterial esters, for example, esters of para-hydroxybenzoic acid; and other anti-microbial agents such as chlorhexidine, chlorocresol, and polymyxin.
- quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimide, dequalinium chloride, and cetylpyridinium chloride
- mercurial agents such as phenylmercuric nitrate, phenylmercuric
- Suitable chelating agents include, but are not limited to, deferoxamine, ditiocarb sodium, edetate calcium disodium, edetate disodium, edetate sodium, edetate trisodium, penicillamine, pentetate calcium trisodium, pentetic acid, succimer, trientin.
- the pH of the composition is within the range of from about 2 to about 9, more preferably, about 3 to about 7, even more preferably about 4 to about 5, and optimally about 4.5.
- the pH can be adjusted by adding an aqueous acid or base, dropwise to the composition until the desired pH is obtained.
- any physiologically acceptable pH adjusting acids, bases or buffers are acceptable, e.g., acids, such as acetic, boric, citric, lactic, phosphoric, hydrochloric; bases, such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, THAM (trishydroxymethylaminomethane); and buffers such as citrate/dextrose, sodium bicarbonate, ammonium chloride and mixtures thereof, preferably, 0.1 normal hydrochloric acid for a pH of less than 7 and 0.1 normal aqueous sodium hydroxide for a pH of greater than 7.
- acids such as acetic, boric, citric, lactic, phosphoric, hydrochloric
- bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, THAM (trishydroxymethylaminomethane)
- buffers such as citrate/dextrose, sodium bicarbonate, ammonium chloride and mixture
- composition of the invention can also comprise NMDA receptor antagonists including, but not limited to, dextromethorphan, dextrorphan, ketamine, pyroloquinolin quinone, cis-4-(phosphonomethyl)-2-piperidine carboxylic acid, MK801, memantine, D-methadone, or pharmaceutically-acceptable salts thereof.
- NMDA receptor antagonists including, but not limited to, dextromethorphan, dextrorphan, ketamine, pyroloquinolin quinone, cis-4-(phosphonomethyl)-2-piperidine carboxylic acid, MK801, memantine, D-methadone, or pharmaceutically-acceptable salts thereof.
- compositions of the invention can also include other excipients and pharmaceuticals.
- excipients that can be included in the topical compositions of the invention include, but are not limited to, antibiotics, analgesics, antifingal agents, non-steroidal anti-inflammatory agents, anti-tussive agents, expectorants, glucocorticoids, vitamins, anti-oxidants, flavoring agents, sweetening agents, iso-osmotic agents, moisturizers, emollients, buffering agents, solubilizing agents, penetration agents, protectants, surfactants, and propellants, and other conventional systemic or topical pain relief therapies, analgesics, and pharmaceuticals.
- antibiotics include, but are not limited to, aminoglycoside antibiotics; such as apramycin, arbekacin, bambermycins, butirosin, dibekacin, neomycin, neomycin undecylenate, netilmicin, paromomycin, ribostamycin, sisomicin, and spectinomycin; amphenicol antibiotics, such as azidamfenicol, chloramphenicol, florfenicol, and thiamphenicol; ansamycin antibiotics, such as rifamide and rifampin; carbacephems, such as loracarbef; carbapenems, such as biapenem and imipenem; cephalosporins, such as cefaclor, cefadroxil, cefamandole, cefatrizine, cefazedone, cefazedone, cefozopran, cefpimizole, cefpiramide, and cef
- analgesics include, but are not limited to, aceclofenac, acetaminophen, acetaminosalol, acetanilide, acetylsalicylsalicylic acid, alclofenac, alminoprofen, aloxiprin, aluminum bis(acetylsalicylate), aminochlorthenoxazin, 2-amino-4-picoline, aminopropylon, aminopyrine, ammonium salicylate, amtolmetin guacil, antipyrine, antipyrine salicylate, antrafenine, apazone, aspirin, benorylate, benoxaprofen, benzpiperylon, benzydamine, bermoprofen, bromfenac, p-bromoacetanilide, 5-bromosalicylic acid acetate, bucetin, bufexamac, bumadizon, butacetin, calcium acetylsalicylate,
- Suitable antifungal agents include, but are not limited to, polyenes, such as amphotericin b, candicidin, mepartricin, natamycin, and nystatin; allylamines, such as butenafine, and naftifine; imidazoles, such as bifonazole, butoconazole, chlordantoin, flutrimazole, isoconazole, ketoconazole, and lanoconazole; thiocarbamates, such as tolciclate, tolindate, and tolnaftate; triazoles, such as fluconazole, itraconazole, saperconazole, and terconazole; and others, such as bromosalicylchloranilide, buclosamide, calcium propionate, chlorphenesin, and ciclopirox; and others, such as azaserine, griseofulvin, oligomycins, neomycin undecylenate,
- non-steroidal anti-inflammatory agents include, but are not limited to, aminoarylcarboxylic acid derivatives, such as enfenamic acid, etofenamate, flufenamic acid, isonixin, meclofenamic acid, mefenamic acid, niflumic acid, talniflumate, terofenamate, and tolfenamic acid; arylacetic acid derivatives, such as aceclofenac, acemetacin, alclofenac, amfenac, amtolmetin guacil, bromfenac, bufexamac, cimnetacin, clopirac, diclofenac sodium, etodolac, felbinac, fenclozic acid, fentiazac, glucametacin, ibufenac, indomethacin, isofezolac isoxepac, lonazolac, metiazinic
- antitussive agents include, but are not limited to, alloclamide, amicibone, benproperine, benzonatate, bibenzonium bromide, bromoform, butamirate, butethamate, caramiphen ethanedisulfonate, carbetapentane, chlophedianol, clobutinol, cloperastine, codeine, codeine methyl bromide, codeine ⁇ -oxide, codeine phosphate, codeine sulfate, cyclexanone, dimethoxanate, dropropizine, drotebanol, eprazinone, ethyl dibunate, ethylmorphine, fominoben, guaiapate, hydrocodone, isoaminile, levopropoxyphene, morclofone, narceine, mormethadone, noscapine, oxeladin, oxolamine,
- Example of suitable expectorants include, but are not limited to, ambroxol, ammonium bicarabonate, ammonium carbonate, bromhexine, calcium iodide, carbocysteine, guaiacol, guaiacol benzoate, guaiacolcarbonate, guaiacol phosphate, guaifenesin, guaithylline, hydriodic acid, iodinated glycerol, potassium guaiacolsulfonate, potassium iodide, sodium citrate, sodium iodide, storax, terebene, terpin, and trifolium.
- Suitable glucocorticoids include, but are not limited to, 21 -acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, flucortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, flupre
- Suitable vitamins include, but are not limited to calcipotriene, calcitriol, ergosterol, 1 ⁇ -hydroxycholecalciferol, vitamin D 2+ , vitamin D 3+ , ascorbic acid, calcium ascorbate, nicotinamide ascorbate, sodium ascorbate, ⁇ -carotene, ⁇ -carotene, ⁇ -carotene, vitamin ⁇ , cobamamide, folic acid, hydroxocobalamin, sodium folate, vitamin B 12 , menadiol, menadione, menadoxime, menaquinones, phylloquinone, vitamin K 5+ , inositol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, vitamin E, vitamin E acetate, and vitamin U.
- Suitable anti-oxidants include, but are not limited to, ascorbic acid, sodium ascorb ate, sodium bisulfite, sodium thio sulfate, 8-hydroxy quinoline, and N-acetyl cysterine.
- suitable flavoring agents include, but are not limited to, oil of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, marjoram, cinnamon, lemon, and orange, and methyl salicylate.
- suitable sweetening agents include, but not limited to, sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, perillartine, AMP (aspartyl phenyl alanine, methyl ester), and saccharine.
- compositions of the present invention optionally can include an iso-osmotic agent which functions to prevent irritation of the mucosa by the composition.
- iso-osmotic agents which can be used include sodium chloride, dextrose, and calcium chloride.
- the amount of local anesthetic in the composition is within the range of from about 0.005 percent to about 2 percent of the total weight of the composition, more preferably, of from about 0.01 percent to about 0.5 percent of the total weight of the composition.
- a preferred concentration of local anesthetic is from about 0.02 percent to about 0.1 percent of the total weight of the composition, more preferably, about 0.04 percent to about 0.08 percent.
- a preferred concentration of local anesthetic is from about 0.1 percent to about 0.4 percent of the total weight of the composition, more preferably, about 0.2 percent to about 0.3 percent.
- the amount of opioid in the composition is within the range of from about 0.005 percent to about 3 percent of the total weight of the composition, more preferably, of from about 0.01 percent to about 2 percent, still more preferably, of from about 0.05 percent to about 1 percent of the total weight of the composition.
- a preferred concentration of opioid is from about 0.1 percent to about 0.3 percent of the total weight of the composition.
- a preferred concentration of opioid is from about 0.3 percent to 20 about 0.8 percent of the total weight of the composition, more preferably, about 0.4 percent to about 0.5 percent.
- the amount of mucoadhesive in the composition is within the range of from about 0.1 percent to about 40 percent of the total weight of the composition, more preferably, of from about 10 percent to about 30 percent, and optimally, of from about 15 percent to about 25 percent of the total weight of the composition.
- the amount of water in the composition is within the range of from about 95 percent to about 10 percent of the total weight of the composition, more preferably, of from about 90 percent to about 50 percent, and optimally, of from about 85 percent to about 75 percent of the total weight of the composition.
- a chelating agent when used, preferably, it is present in an amount within the range of from about 0.005 percent to about 1 percent of the total weight of the composition, more preferably, of from about 0.01 percent to about 0.5 percent, still more preferably, of from about 0.05 percent to about 0.2 percent of the composition.
- a preservative when used, preferably, it is present in an amount within the range of from about 0.0001 percent to about 0.2 percent of the total weight of the composition, more preferably, of from about 0.0005 percent to about 0.1 percent, and optimally, of from about 0.001 percent to about 0.05 percent of the total weight of the composition.
- compositions or the invention are topically applied directly to the affected area.
- the compositions of the invention can be applied to the affected area of the mucous membrane in any conventional manner well known in the art, for example, as a mist via an aerosol applicator, by cannula, via a patch, by a dropper, or by an applicator stick, preferably as a mist, more preferably as a metered-dose mist.
- a mist can be sprayed onto the area to be treated via an aerosol container, pressurized or non-pressurized, preferably a non-pressurized pump.
- a cannula can be used.
- the cannula can be attached to a pressurized or non-pressurized pump, preferably a non-pressurized pump.
- a suitable non-pressurized pump for application of compositions of the invention can comprise a container, a valve, an actuator, and optionally a dip tube.
- the non-pressurized pump's container can be metal, such as a tin plated steel or aluminum, glass, or plastic.
- the valve's primary purpose is to regulate the flow of product from the container. It provides a means of discharging the desired amount.
- Suitable spray valves are described in Remington's Pharmaceutical Sciences 18th Edition, ed. Alfonso Gennaro, Mack Publishing Co. Easton, Pa., 1990 pp. 1703-1704, incorporated herein by reference.
- the actuator provides a means for releasing the contents from a pressurized container. Suitable actuators are described in Remington's Pharmaceutical Sciences 18th Edition, ed. Alfonso Gennaro, Mack Publishing Co. Easton, Pa., 1990 pp. 1704-1705, incorporated herein by reference.
- the metered pump is a VP 7 Screw-On Pump (90 ⁇ l, 18/415) commercially available from Valois of America, Inc. (Greenwich, Conn.).
- the VP 7 screw-on pump is manufactured from polyethylene and polypropylene. It is designed in a way such that the hydraulically opening clapper eliminates the use of any elastomeric gaskets in contact with the product.
- the pump has an annular dosing chamber, which fills only at the full return of the actuator to ensure full dosing and precision.
- the preferred actuator is the 132C-BL GP4 BL long throat actuator commercially available from Valois Pharmaceuticals, Inc.
- the actuator is manufactured from polyethylene and polypropylene and, preferably, contains a captive insert to provide a well-atomized spray pattern. The captive insert also reduces the dead volume in the actuator.
- the preferred actuator is a stainless-steel cannula of about 73 mm in length, for example, the 215 stainless-steel cannula commercially available from Valois Pharmaceuticals, Inc. Polyethylene or polypropylene cannulas can also be used.
- compositions of the invention can also be delivered to the buccal or nasal cavity via a patch that is applied adjacent to the area of skin to be treated.
- a “patch” comprises at least a composition of the invention and a covering layer, such that, the patch can be placed over the area to be treated.
- the patch is designed to maximize local delivery and to minimize absorption into the circulatory system, reduce lag time, promote uniform absorption, and reduce mechanical rub-off.
- Suitable patches are described in Transdermal and Topical Drug Delivery Systems, Interpharm Press, Inc. p. 249-297, incorporated herein by reference.
- Suitable patches for buccal delivery of compositions of the invention is disclosed in U.S. Pat. Nos . 5,713,852 and 4,900,552, both of which are incorporated herein by reference.
- composition of the invention applied to the buccal or nasal passages will vary depending on the particular mucoadhesive, local anesthetic, and opioid used; the nature and severity of the mucosal lesion or inflamation being treated, and the subject.
- the composition should be applied to the affected area as recommended by a physician, preferably, as needed by the patient to relieve pain. For example, a dose of about 0.05 mg to about 4 mg morphine sulfate and 0.02 mg to about 3 mg of lidocaine hydrochloride in about 0.5g to about 3 g of composition can be delivered to the affected area.
- a dose of about 2 mg morphine sulfate and about 1 mg lidocaine hydrochloride in about 1.5 g of composition can be delivered to the affected area.
- a dose of about 2 mg morphine sulfate and about 1 mg lidocaine hydrochloride in about 0.4 g of composition can be delivered to the affected area.
- the dose is delivered with a spray actuator in about 8 to about 20 separate spray shots, more preferably about 16 spray shots, wherein each spray shot weighs about 50 mg to about 150 mg, more preferably about 100 mg.
- the dose is delivered via cannula in about 4 spray shots, wherein each spray shot weighs about 100 mg.
- a composition of the present invention is described in Table 2 below.
- Morphine sulfate pentahydrate (122.6 mg), lidocaine (65.4 mg) hydrochloride monohydrate, and edetate disodium dihydrate (100 mg) were dissolved in 80 g of sterile water.
- the resulting solution was cooled to 10° C. in an ice bath and poloxmer 407 (20g) was slowly added with mixing until the Poloxmer 407 completely dissolved.
- the solution was maintained at about 10° C. until the foam collapsed.
- About 4 g of the solution was added to a 5 ml vial and a Valois VP7/90 18/415 pump was screwed onto the vial and refrigerated at 4° C. for 30 minutes.
- the vial was removed from the refrigerator and the metered pump was primed using the Valois 165 actuator.
- the Valois 165 actuator was removed and the filled vial was stored at 4° C. until the foam collapsed.
- the vial was removed from the refrigerator and kept at room temperature (25° C.) until the contents gelled.
- the viscosity of the above-prepared oral spray was measure using a Brookfield RVT viscometer. At 30° C. the viscosity was 82,666 cps (averaged over three determinations) and at 40° C. the viscosity was 95,666 cps (averaged over three determinations).
- the composition can be applied as follows. Attach the long throat actuator to the metering pump and store the unit at 4° C. for at least 30 minutes. To prime the pump (7-8 sprays), with actuator in the up position, press the actuator firmly and quickly to spray into a waste container, hold the actuator for about one second when it is in the pressed position following each spray. With actuator in the up position, press the actuator firmly and quickly to spray onto the surface of the subject to be treated. Hold the actuator for two to three seconds when it is in the pressed position following each spray. Apply a total of 16 spray shots of for a total application of about 2 mg morphine sulfate and about 1 mg lidocaine hydrochloride in about 1.5 g of composition.
- the liquid will form a viscous mucoadhesive gel. If it takes more than 90 seconds to apply 16 spray shots, store the unit at 4° C. for 10 minutes to cool the content before further usage.
- a second composition of the present invention is described in Table 2 below.
- Morphine sulfate pentahydrate (490.48 mg), lidocaine (261.6 mg) hydrochloride monohydrate, and edetate disodium dihydrate (100 mg ) were dissolved in 80 g of sterile water.
- the resulting solution was cooled to 10° C. in an ice bath and poloxmer 407 (20g) was slowly added with mixing until the Poloxmer 407 completely dissolved.
- the solution was maintained at about 10° C. until the foam collapsed.
- About 4 g of the solution was added to a 5 ml vial and a Valois VP7/90 18/415 pump was screwed onto the vial and refrigerated at 4° C. for 30 minutes.
- the vial was removed from the refrigerator and the metered pump was primed using the Valois 165 actuator.
- the Valois 165 actuator was removed and the filled vial was stored at 4° C. until the foam collapsed.
- the vial was removed from the refrigerator and kept at room temperature (25° C.) until the contents gelled.
- the viscosity of the above-prepared oral spray was measure using a Brookfield RVT viscometer. At 30° C. the viscosity was 81,000 cps (averaged over three determinations) and at 40° C. the viscosity was 94,333 cps (averaged over three determinations).
- composition can be applied using a long-throat actuator as described above (for spray application) or by cannula (for application to a specific area). A total of 4 spray shots is recommended.
- the preferred actuator is a stainless-steel cannula of about 73 mm in length, for example, the 215 stainless-steel cannula commercially available from Valois Pharmaceuticals, Inc.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Lubricants (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/888,466 US20020013331A1 (en) | 2000-06-26 | 2001-06-25 | Methods and compositions for treating pain of the mucous membrane |
US10/172,455 US6509028B2 (en) | 2000-06-26 | 2002-06-17 | Methods and compositions for treating pain of the mucous membrane |
US10/347,385 US20030124190A1 (en) | 2000-06-26 | 2003-01-21 | Methods and compositions for treating pain of the mucous membrane |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22216400P | 2000-06-26 | 2000-06-26 | |
US09/888,466 US20020013331A1 (en) | 2000-06-26 | 2001-06-25 | Methods and compositions for treating pain of the mucous membrane |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/172,455 Continuation US6509028B2 (en) | 2000-06-26 | 2002-06-17 | Methods and compositions for treating pain of the mucous membrane |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020013331A1 true US20020013331A1 (en) | 2002-01-31 |
Family
ID=22831130
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/888,466 Abandoned US20020013331A1 (en) | 2000-06-26 | 2001-06-25 | Methods and compositions for treating pain of the mucous membrane |
US10/172,455 Expired - Lifetime US6509028B2 (en) | 2000-06-26 | 2002-06-17 | Methods and compositions for treating pain of the mucous membrane |
US10/347,385 Abandoned US20030124190A1 (en) | 2000-06-26 | 2003-01-21 | Methods and compositions for treating pain of the mucous membrane |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/172,455 Expired - Lifetime US6509028B2 (en) | 2000-06-26 | 2002-06-17 | Methods and compositions for treating pain of the mucous membrane |
US10/347,385 Abandoned US20030124190A1 (en) | 2000-06-26 | 2003-01-21 | Methods and compositions for treating pain of the mucous membrane |
Country Status (11)
Country | Link |
---|---|
US (3) | US20020013331A1 (de) |
EP (1) | EP1296650B1 (de) |
JP (2) | JP2004501181A (de) |
AT (1) | ATE289802T1 (de) |
AU (1) | AU2001270177A1 (de) |
CA (1) | CA2413545A1 (de) |
DE (1) | DE60109164T2 (de) |
ES (1) | ES2239144T3 (de) |
IL (2) | IL153656A0 (de) |
PT (1) | PT1296650E (de) |
WO (1) | WO2002000195A2 (de) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040019022A1 (en) * | 2002-07-25 | 2004-01-29 | Karen Stec | Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals |
US6685917B2 (en) | 2000-11-22 | 2004-02-03 | Rxkinetix, Inc. | Treatment of mucositis |
US20040209852A1 (en) * | 2003-04-16 | 2004-10-21 | Imtiaz Chaudry | Formulations and methods for treating rhinosinusitis |
US20040208830A1 (en) * | 2003-04-16 | 2004-10-21 | Imtiaz Chaudry | Nasal pharmaceutical formulations and methods of using the same |
US20040208831A1 (en) * | 2003-04-16 | 2004-10-21 | Imtiaz Chaudry | Nasal pharmaceutical formulations and methods of using the same |
US20050136116A1 (en) * | 2003-12-18 | 2005-06-23 | Keith Whitehead | Stabilized prednisolone sodium phosphate solutions |
US20050256193A1 (en) * | 2002-02-27 | 2005-11-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
US20070020187A1 (en) * | 2005-07-22 | 2007-01-25 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
US20070128284A1 (en) * | 2005-11-30 | 2007-06-07 | Endo Pharmaceuticals Inc. | Treatment of xerostomia |
US20070264289A1 (en) * | 2003-06-12 | 2007-11-15 | Eot Research Inc. | Compositions and methods of administering doxepin to mucosal tissue |
WO2008060764A2 (en) * | 2006-10-05 | 2008-05-22 | Drugtech Corporation | Topical therapies for oral mucositis and other conditions |
US20080214664A1 (en) * | 2007-03-02 | 2008-09-04 | Combe Incorporated | Anesthetic spray composition |
US20090004248A1 (en) * | 2007-06-29 | 2009-01-01 | Frank Bunick | Dual portion dosage lozenge form |
US20090035385A1 (en) * | 2004-12-22 | 2009-02-05 | Drugtech Corporation | Compositions including iron |
US20090042968A1 (en) * | 2004-12-23 | 2009-02-12 | Roxro Pharma, Inc. | Therapeutic compositions for intranasal administration of ketorolac |
US20090068259A1 (en) * | 2007-09-06 | 2009-03-12 | Shira Pilch | Controlled Surface Gelling of Mucoadhesive Polymers on Oral Mucosa |
US20110091618A1 (en) * | 2009-10-16 | 2011-04-21 | Frito-Lay North America, Inc. | Method for preventing oxidation and off flavors in high carotenoid foods |
US10722586B2 (en) | 2014-11-10 | 2020-07-28 | Universidade Federal De Pelotas | Filmogenic compositions for topical anaesthetic bioadhesives—tabs, for controlled release of active principles and topical anaesthetic bioadhesives |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
US7592304B2 (en) * | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
US20030158111A1 (en) * | 1999-10-01 | 2003-08-21 | David Bar-Or | Methods and products for oral care |
US9616150B2 (en) * | 1999-10-29 | 2017-04-11 | Children's Hospital Los Angeles | Bone hemostasis method and materials |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
PL207845B1 (pl) | 2000-07-31 | 2011-02-28 | Nycomed Danmark As | Spray donosowy do dostarczania kompozycji farmaceutycznej zawierającej fentanyl i zastosowanie soli fentanylu do wytwarzania środka leczniczego |
US20080182841A1 (en) * | 2001-10-29 | 2008-07-31 | Levine Howard L | Vaginally administered anti-dysrhythmic agents for treating pelvic pain |
US8425892B2 (en) * | 2001-10-29 | 2013-04-23 | Columbia Laboratories, Inc. | Extended, controlled-release pharmaceutical compositions using charged polymers |
US20030114394A1 (en) * | 2001-10-29 | 2003-06-19 | Levine Howard L. | Vaginally administered anti-dysrhythmic agents for treating pelvic pain |
US6602490B1 (en) * | 2002-03-04 | 2003-08-05 | Richard A. Cloonan | Dental cleaning formulation and manufacturing process |
US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
GB0213869D0 (en) * | 2002-06-17 | 2002-07-31 | Arakis Ltd | The treatment of pain |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
US20040213828A1 (en) * | 2003-04-23 | 2004-10-28 | Smith David J. | Pain relief lollipop compositions and methods |
US20050266090A1 (en) * | 2003-04-29 | 2005-12-01 | Ales Prokop | Nanoparticular targeting and therapy |
WO2004100884A2 (en) * | 2003-05-07 | 2004-11-25 | Dmi Biosciences, Inc. | Oral care methods and products |
US7106483B2 (en) * | 2003-06-12 | 2006-09-12 | Ricoh Company, Limited | Optical scanner and image forming apparatus |
GB0315632D0 (en) | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
GB0330049D0 (en) * | 2003-12-24 | 2004-02-04 | Arakis Ltd | The treatment of neuropathic pain conditions |
JP2007517806A (ja) * | 2004-01-15 | 2007-07-05 | オーラル バイオサイエンス ピーティーワイ. リミテッド | 口腔用麻酔ゲル |
US20060115785A1 (en) * | 2004-11-30 | 2006-06-01 | Chunhua Li | Systems and methods for intra-oral drug delivery |
US7947508B2 (en) * | 2004-11-30 | 2011-05-24 | Align Technology, Inc. | Systems and methods for intra-oral diagnosis |
US20060115782A1 (en) * | 2004-11-30 | 2006-06-01 | Chunhua Li | Systems and methods for coating a dental appliance |
US7766658B2 (en) * | 2004-11-30 | 2010-08-03 | Align Technology, Inc. | Systems and methods for intra-oral diagnosis |
US20060252010A1 (en) * | 2005-05-09 | 2006-11-09 | Sunnen Gerard V | Sodium chloride pad for treatment of dental conditions |
US20080248090A1 (en) * | 2005-05-09 | 2008-10-09 | Sunnen Gerard V | Graduated concentration sodium chloride patches for the treatment of dental conditions |
EP1749528A1 (de) | 2005-08-05 | 2007-02-07 | Pharma C S.A. | Pharmazeutische Kombinationen, welche mu-opioid Agonisten und Inhibitoren der Stickstoffmonoxidherstellung enthalten |
US8623334B1 (en) | 2005-09-29 | 2014-01-07 | Alan J. Wickenhauser | Topical anesthetic |
US8263047B2 (en) * | 2005-09-29 | 2012-09-11 | Wickenhauser Alan J | Topical anesthetic for dental procedures |
JP5217136B2 (ja) * | 2005-10-18 | 2013-06-19 | 大正製薬株式会社 | 直腸、尿道および膣適用用半固形状製剤。 |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
WO2007103555A2 (en) * | 2006-03-08 | 2007-09-13 | Nuviance, Inc. | Transdermal drug delivery compositions and topical compositions for application on the skin |
US20070231396A1 (en) * | 2006-03-29 | 2007-10-04 | Ray Charles D | Medication spray formulation |
US20070248657A1 (en) * | 2006-04-25 | 2007-10-25 | Smith David J | Multi-compartment transdermal pain control device |
JP5537152B2 (ja) * | 2006-08-01 | 2014-07-02 | フリクサス ファーマシューティカルズ, インコーポレイテッド | 慢性進行性心不全のための処置 |
EP1964552B1 (de) * | 2007-03-02 | 2009-08-26 | Flamek Corp OÜ | Analgesische Zusammensetzung von topisch angewendeten, nichtsteroiden und entzündungshemmenden Arzneimitteln und Opioiden |
US20080305149A1 (en) * | 2007-06-11 | 2008-12-11 | Thomas Hirt | Mucoadhesive vesicles for drug delivery |
CA2699087A1 (en) * | 2007-09-11 | 2009-04-16 | Dorian Bevec | Use of a peptide as a therapeutic agent |
US20090093547A1 (en) * | 2007-10-09 | 2009-04-09 | Sciele Pharma, Inc. | Compositions and Methods for Treating Premature Ejaculation |
US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
MX349677B (es) | 2007-11-13 | 2017-08-08 | Meritage Pharma Inc | Composiciones corticosteroides. |
US20090131386A1 (en) * | 2007-11-13 | 2009-05-21 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
US20090123551A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
ES2436781T3 (es) | 2007-12-17 | 2014-01-07 | The Regents Of The University Of Michigan | Composiciones y procedimientos de tratamiento y prevención de deficiencias de músculo esquelético |
US20090264392A1 (en) * | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
KR20210107137A (ko) | 2008-04-21 | 2021-08-31 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
CA2731769C (en) | 2008-07-21 | 2013-09-10 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
DE102008037682A1 (de) | 2008-08-14 | 2010-04-08 | Strackharn, Klaus, Dr.med. | Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen |
HUE051538T2 (hu) | 2008-08-20 | 2021-03-01 | Univ California | Kortikoszteroidok a gyomor-bél traktus gyulladásos betegségeinek kezelésére |
US20100221313A1 (en) * | 2008-12-01 | 2010-09-02 | Innovative Pharmaceuticals, Llc | Transdermal reservoir patch |
US20110097401A1 (en) * | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
US9549842B2 (en) | 2011-02-04 | 2017-01-24 | Joseph E. Kovarik | Buccal bioadhesive strip and method of treating snoring and sleep apnea |
US8701671B2 (en) | 2011-02-04 | 2014-04-22 | Joseph E. Kovarik | Non-surgical method and system for reducing snoring |
US20110117175A1 (en) * | 2009-11-18 | 2011-05-19 | Rosenbaum Richard J | Sweet analgesic for use in medical procedures or treatments |
WO2011066201A2 (en) * | 2009-11-25 | 2011-06-03 | The Regents Of The University Of Michigan | Methods and systems for treating and preventing cardiac injury in dystrophic subjects |
GB2477545B (en) * | 2010-02-05 | 2011-12-21 | Special Products Ltd | A liquid morphine composition for buccal administration |
BR112013011942A2 (pt) | 2010-11-15 | 2016-11-01 | Univ Michigan | formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida. |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
PL2701681T3 (pl) * | 2011-04-29 | 2017-03-31 | Moberg Pharma Ab | Kompozycje farmaceutyczne zawierające środek miejscowo znieczulający, taki jak bupiwakaina, do podawania miejscowego do jamy ustnej lub gardła |
US8387798B1 (en) | 2012-04-27 | 2013-03-05 | Abdulmohsen E. A. H. Al-Terki | Mutiple oral and nasal surgical procedures method and kit |
US10022083B2 (en) | 2011-06-02 | 2018-07-17 | Abdulmohsen E. A. H. Al-Terki | Multiple oral and nasal surgical procedures method and kit |
CA2865593A1 (en) * | 2012-02-27 | 2013-09-06 | Eye Therapies Llc | Compositions and methods for the treatment of migraine |
FR2994844B1 (fr) * | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | Formulation gelifiante a base de ketamine |
BR112015014966A2 (pt) | 2012-12-20 | 2017-07-11 | Colgate Palmolive Co | composição de cuidado oral contendo líquidos iônicos |
MX354123B (es) | 2013-02-07 | 2018-02-14 | Galvan Gonzalez Tomas Bernardo | Composición antiséptica oral para tratamiento de mucositis oral. |
US20140371305A1 (en) * | 2013-06-14 | 2014-12-18 | Professional Compounding Centers Of America | Mupirocin Antibiotic Composition |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
WO2016070826A1 (zh) * | 2014-11-05 | 2016-05-12 | 四川海思科制药有限公司 | 一种罗哌卡因缓释凝胶制剂及其制备与应用 |
US9943074B2 (en) * | 2015-02-27 | 2018-04-17 | Stanley James Balgaard | Hinging and rotating coupler mechanism for avian spinning wing decoy |
AU2016298307A1 (en) | 2015-07-28 | 2018-02-15 | Otonomy, Inc. | TrkB or TrkC agonist compositions and methods for the treatment of OTIC conditions |
CA3029281A1 (en) | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
SG11201908629WA (en) | 2017-04-19 | 2019-10-30 | Otsuka Pharma Factory Inc | Anti-inflammatory agent |
WO2019154895A1 (en) | 2018-02-08 | 2019-08-15 | Strekin Ag | Gel formulation for preventing or treating hearing loss |
JP6886551B1 (ja) * | 2020-11-06 | 2021-06-16 | 医療法人祥和会 | 歯科用の局所麻酔液 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4051234A (en) | 1975-06-06 | 1977-09-27 | The Procter & Gamble Company | Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies |
GB2042888B (en) | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
US5225196A (en) | 1983-11-14 | 1993-07-06 | Columbia Laboratories, Inc. | Bioadhesive compositions and methods of treatment therewith |
DE3522550A1 (de) | 1985-06-24 | 1987-01-02 | Klinge Co Chem Pharm Fab | Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung |
US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
US4806543A (en) * | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
US4855142A (en) | 1987-02-27 | 1989-08-08 | Ciba-Geigy Corporation | Pharmaceutical plaster |
US5906810A (en) | 1987-03-17 | 1999-05-25 | Turner; Robert E. | Formulations and uses thereof in the prevention and treatment of oral lesions |
IL87710A (en) * | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
US4900552A (en) | 1988-03-30 | 1990-02-13 | Watson Laboratories, Inc. | Mucoadhesive buccal dosage forms |
US5219861A (en) | 1988-12-21 | 1993-06-15 | Chugai Seiyaku Kabushiki Kaisha | 6 β-Thiomorphine derivatives |
US5292362A (en) | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US5112620A (en) * | 1990-09-20 | 1992-05-12 | Mikkur, Inc. | Polyethylene glycol ointment for apthous ulcers |
SE9003665D0 (sv) | 1990-11-16 | 1990-11-16 | Kabivitrum Ab | Morphine prodrugs |
US5662924A (en) | 1991-03-21 | 1997-09-02 | Smith & Nephew Plc | Wound dressing |
IT1248014B (it) * | 1991-06-07 | 1995-01-05 | Inverni Della Beffa Spa | Preparazioni oftalmiche a rilascio protratto |
US5206248A (en) * | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
US5972906A (en) | 1991-07-03 | 1999-10-26 | Hyal Pharmaceutical Corporation | Treatment of mucous membrane disease, trauma or condition and for the relief of pain thereof |
US5589840A (en) | 1991-11-05 | 1996-12-31 | Seiko Epson Corporation | Wrist-type wireless instrument and antenna apparatus |
GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
DE4223004A1 (de) | 1992-07-13 | 1994-01-20 | Liedtke Pharmed Gmbh | Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie |
US5234929A (en) * | 1992-07-20 | 1993-08-10 | William Chelen | Method of treating motion sickness with anticonvulsants and antitussive agents |
EP0656779B1 (de) | 1992-08-28 | 2000-04-12 | Pharmos Corporation | Emulsionen im submikron-bereich als vehikel zur arzneistoffverabreichung am auge |
US5922340A (en) | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
US5817625A (en) | 1992-09-21 | 1998-10-06 | Oncogene Science, Inc. | Methods of prevention of oral mucositis with transforming growth factor beta |
ES2239369T3 (es) | 1993-03-26 | 2005-09-16 | Franciscus Wilhelmus Henricus Maria Merkus | Composiciones farmaceuticas para administracion intranasal de dihidroergotamina. |
US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
US5578315A (en) * | 1993-12-01 | 1996-11-26 | Rutgers, The State University Of New Jersey | Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity |
US5395318A (en) | 1994-01-24 | 1995-03-07 | Kaprelian; Edward K. | Method and apparatus for wound treatment |
US5458879A (en) | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
TW438601B (en) | 1994-05-18 | 2001-06-07 | Janssen Pharmaceutica Nv | New mucoadhesive emulsion compositions and a process for the preparation thereof |
US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
IT1273742B (it) | 1994-08-01 | 1997-07-09 | Lifegroup Spa | Composizioni ad elevata bioadesivita' e mucoadesivita' utili per il trattamento di epitali e mucose |
ATE223202T1 (de) | 1994-09-30 | 2002-09-15 | Mika Pharma Ges Fuer Die Entwi | Pharmazeutische zusammensetzung |
US5635540A (en) | 1994-12-09 | 1997-06-03 | The University Of Virginia Patent Foundation | Stabilized topical pharmaceutical preparations |
US5626878A (en) * | 1995-01-10 | 1997-05-06 | Warner Lambert Company | Reduction of electrostatic forces between magnesium trisilicate adsorbates |
US5866143A (en) | 1995-03-24 | 1999-02-02 | El Khoury And Stein, Ltd. | Topical application of opioid drugs such as morphine for relief of itching and skin disease |
US5713852A (en) | 1995-06-07 | 1998-02-03 | Alza Corporation | Oral dosage and method for treating painful conditions of the oral cavity |
US5948389A (en) * | 1995-06-07 | 1999-09-07 | El Khoury & Stein, Ltd. | Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics |
WO1997000275A2 (en) * | 1995-06-16 | 1997-01-03 | Gel Sciences, Inc. | Responsive polymer networks and methods of their use |
JP2002516617A (ja) * | 1995-06-16 | 2002-06-04 | メドロジック グローバル コーポレイション | 反応性ポリマー網状構造体及びその使用法 |
US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
US5849322A (en) | 1995-10-23 | 1998-12-15 | Theratech, Inc. | Compositions and methods for buccal delivery of pharmaceutical agents |
FR2742989B1 (fr) | 1995-12-29 | 1998-01-23 | Adir | Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs |
US5646151A (en) | 1996-03-08 | 1997-07-08 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
US5667773A (en) | 1996-03-12 | 1997-09-16 | Adolor Corporation | Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith |
US5972932A (en) * | 1996-03-25 | 1999-10-26 | Eli Lilly And Company | Anesthetic method and composition |
US5747060A (en) | 1996-03-26 | 1998-05-05 | Euro-Celtique, S.A. | Prolonged local anesthesia with colchicine |
SE9601421D0 (sv) * | 1996-04-12 | 1996-04-12 | Astra Ab | New composition |
US5846971A (en) | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
US5976573A (en) | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
EP0829481A1 (de) | 1996-09-16 | 1998-03-18 | Pfizer Inc. | Morphinan-Hydroxamsäure-Derivate |
US5955097A (en) | 1996-10-18 | 1999-09-21 | Virotex Corporation | Pharmaceutical preparation applicable to mucosal surfaces and body tissues |
DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
US5942243A (en) | 1996-11-12 | 1999-08-24 | Polytherapeutics, Inc. | Mucoadhesive compositions for administration of biologically active agents to animal tissue |
PT946157E (pt) * | 1996-12-16 | 2002-07-31 | Alcon Lab Inc | Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular |
US5811078A (en) | 1997-03-14 | 1998-09-22 | Adolor Corporation | Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith |
US5798093A (en) | 1997-03-14 | 1998-08-25 | Adolor Corporation | Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith |
US5855907A (en) | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
US5849762A (en) | 1997-07-14 | 1998-12-15 | Adolor Corporation | Peripherally acting anti-pruritic opiates |
US5760023A (en) | 1997-07-14 | 1998-06-02 | Adolor Corporation | Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith |
US5989535A (en) | 1997-08-15 | 1999-11-23 | Soma Technologies | Polymeric bioadhesive emulsions and suspensions and methods of treatment |
ES2252865T3 (es) * | 1997-09-26 | 2006-05-16 | Noven Pharmaceuticals, Inc. | Composiciones bioadhesivas y metodos para la administracion topica de agentes activos. |
US5885597A (en) | 1997-10-01 | 1999-03-23 | Medical Research Industries,Inc. | Topical composition for the relief of pain |
CA2314893C (en) * | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
WO1999045906A1 (en) * | 1998-03-09 | 1999-09-16 | Trustees Of Tufts College | Treatment of compulsive behaviours in man and animals |
IL140834A0 (en) | 1998-07-16 | 2002-02-10 | Sloan Kettering Inst Cancer | Topical compositions comprising an opioid analgesic and an nmda antagonist |
FR2781156B1 (fr) * | 1998-07-20 | 2001-06-29 | Lafon Labor | Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
-
2001
- 2001-06-25 US US09/888,466 patent/US20020013331A1/en not_active Abandoned
- 2001-06-26 AT AT01948733T patent/ATE289802T1/de not_active IP Right Cessation
- 2001-06-26 DE DE60109164T patent/DE60109164T2/de not_active Expired - Fee Related
- 2001-06-26 CA CA002413545A patent/CA2413545A1/en not_active Abandoned
- 2001-06-26 EP EP01948733A patent/EP1296650B1/de not_active Expired - Lifetime
- 2001-06-26 ES ES01948733T patent/ES2239144T3/es not_active Expired - Lifetime
- 2001-06-26 JP JP2002504977A patent/JP2004501181A/ja active Pending
- 2001-06-26 PT PT01948733T patent/PT1296650E/pt unknown
- 2001-06-26 AU AU2001270177A patent/AU2001270177A1/en not_active Abandoned
- 2001-06-26 IL IL15365601A patent/IL153656A0/xx unknown
- 2001-06-26 WO PCT/US2001/020322 patent/WO2002000195A2/en active IP Right Grant
-
2002
- 2002-06-17 US US10/172,455 patent/US6509028B2/en not_active Expired - Lifetime
- 2002-12-25 IL IL153656A patent/IL153656A/en not_active IP Right Cessation
-
2003
- 2003-01-21 US US10/347,385 patent/US20030124190A1/en not_active Abandoned
-
2008
- 2008-06-23 JP JP2008163375A patent/JP2009001574A/ja active Pending
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6685917B2 (en) | 2000-11-22 | 2004-02-03 | Rxkinetix, Inc. | Treatment of mucositis |
US20070071824A1 (en) * | 2000-11-22 | 2007-03-29 | Rosenthal Gary J | Treatment of mucositis using N-acetylcysteine |
US20070014860A1 (en) * | 2000-11-22 | 2007-01-18 | Rosenthal Gary J | Treatment of esophagitis |
US20070014861A1 (en) * | 2000-11-22 | 2007-01-18 | Rosenthal Gary J | Treatment of proctitis |
US20050256193A1 (en) * | 2002-02-27 | 2005-11-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
US20070224267A1 (en) * | 2002-02-27 | 2007-09-27 | Uwe Pschorn | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
WO2004010989A1 (en) * | 2002-07-25 | 2004-02-05 | Advances Life Sciences, Inc. | Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals |
US20040019022A1 (en) * | 2002-07-25 | 2004-01-29 | Karen Stec | Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals |
US20050180925A1 (en) * | 2003-04-16 | 2005-08-18 | Dey, L.P. | Formulations and methods for treating rhinosinusitis |
US8309061B2 (en) | 2003-04-16 | 2012-11-13 | Dey Pharma, L.P. | Formulations and methods for treating rhinosinusitis |
US20060051299A1 (en) * | 2003-04-16 | 2006-03-09 | Merck Patent Gmbh | Nasal pharmaceutical formulations and methods of using the same |
US20060051300A1 (en) * | 2003-04-16 | 2006-03-09 | Merck Patent Gmbh | Formulations and methods for treating rhinosinusitis |
US9808471B2 (en) | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
US7811606B2 (en) | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
US20040209852A1 (en) * | 2003-04-16 | 2004-10-21 | Imtiaz Chaudry | Formulations and methods for treating rhinosinusitis |
US9180126B2 (en) | 2003-04-16 | 2015-11-10 | Mylan Specialty L.P. | Formulations and methods for treating rhinosinusitis |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US20040208831A1 (en) * | 2003-04-16 | 2004-10-21 | Imtiaz Chaudry | Nasal pharmaceutical formulations and methods of using the same |
US8663695B2 (en) | 2003-04-16 | 2014-03-04 | Mylan Specialty L.P. | Formulations and methods for treating rhinosinusitis |
US20040208830A1 (en) * | 2003-04-16 | 2004-10-21 | Imtiaz Chaudry | Nasal pharmaceutical formulations and methods of using the same |
US7972626B2 (en) | 2003-04-16 | 2011-07-05 | Merck Patent Gmbh | Fluticasone propionate nasal pharmaceutical formulations and methods of using same |
US20080050442A1 (en) * | 2003-04-16 | 2008-02-28 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
US20080058295A1 (en) * | 2003-04-16 | 2008-03-06 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
US20080058296A1 (en) * | 2003-04-16 | 2008-03-06 | Imtiaz Chaudry | Formulations and methods for treating rhinosinusitis |
US20060039871A1 (en) * | 2003-04-16 | 2006-02-23 | Merck Patent Gmbh | Nasal pharmaceutical formulations and methods of using the same |
US8158154B2 (en) | 2003-04-16 | 2012-04-17 | Dey Pharma, L.P. | Nasal pharmaceutical formulations and methods of using the same |
US8129364B2 (en) | 2003-04-16 | 2012-03-06 | Dey Pharma, L.P. | Formulations and methods for treating rhinosinusitis |
US7972627B2 (en) | 2003-04-16 | 2011-07-05 | Merck Patent Gmbh | Beclomethasone dipropionate monohydrate nasal pharmaceutical formulations and methods of using the same |
US20070264289A1 (en) * | 2003-06-12 | 2007-11-15 | Eot Research Inc. | Compositions and methods of administering doxepin to mucosal tissue |
US20050136116A1 (en) * | 2003-12-18 | 2005-06-23 | Keith Whitehead | Stabilized prednisolone sodium phosphate solutions |
US20110015150A1 (en) * | 2004-12-22 | 2011-01-20 | Drugtech Corporation | Methods of administering compositions including iron |
US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
US20090035385A1 (en) * | 2004-12-22 | 2009-02-05 | Drugtech Corporation | Compositions including iron |
US20090028962A1 (en) * | 2004-12-22 | 2009-01-29 | Drugtech Corporation | Methods and Compositions for Enhancing Iron Absorption |
US20090042968A1 (en) * | 2004-12-23 | 2009-02-12 | Roxro Pharma, Inc. | Therapeutic compositions for intranasal administration of ketorolac |
US8574552B2 (en) | 2005-07-22 | 2013-11-05 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
US10258693B2 (en) | 2005-07-22 | 2019-04-16 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
US20070020187A1 (en) * | 2005-07-22 | 2007-01-25 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
US20070020186A1 (en) * | 2005-07-22 | 2007-01-25 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
US20070128284A1 (en) * | 2005-11-30 | 2007-06-07 | Endo Pharmaceuticals Inc. | Treatment of xerostomia |
US7501452B2 (en) | 2005-11-30 | 2009-03-10 | Endo Pharmaceuticals Inc. | Treatment of xerostomia |
WO2008060764A3 (en) * | 2006-10-05 | 2008-07-24 | Drugtech Corp | Topical therapies for oral mucositis and other conditions |
WO2008060764A2 (en) * | 2006-10-05 | 2008-05-22 | Drugtech Corporation | Topical therapies for oral mucositis and other conditions |
US20080214664A1 (en) * | 2007-03-02 | 2008-09-04 | Combe Incorporated | Anesthetic spray composition |
US20100240749A9 (en) * | 2007-03-02 | 2010-09-23 | Combe Incorporated | Anesthetic spray composition |
US20090004248A1 (en) * | 2007-06-29 | 2009-01-01 | Frank Bunick | Dual portion dosage lozenge form |
US20090068259A1 (en) * | 2007-09-06 | 2009-03-12 | Shira Pilch | Controlled Surface Gelling of Mucoadhesive Polymers on Oral Mucosa |
US10512597B2 (en) * | 2007-09-06 | 2019-12-24 | Colgate-Palmolive Company | Controlled surface gelling of mucoadhesive polymers on oral mucosa |
US20110091618A1 (en) * | 2009-10-16 | 2011-04-21 | Frito-Lay North America, Inc. | Method for preventing oxidation and off flavors in high carotenoid foods |
US10722586B2 (en) | 2014-11-10 | 2020-07-28 | Universidade Federal De Pelotas | Filmogenic compositions for topical anaesthetic bioadhesives—tabs, for controlled release of active principles and topical anaesthetic bioadhesives |
Also Published As
Publication number | Publication date |
---|---|
ATE289802T1 (de) | 2005-03-15 |
DE60109164D1 (de) | 2005-04-07 |
IL153656A (en) | 2010-05-31 |
US20030124190A1 (en) | 2003-07-03 |
US20020192288A1 (en) | 2002-12-19 |
PT1296650E (pt) | 2005-06-30 |
WO2002000195A3 (en) | 2002-08-15 |
US6509028B2 (en) | 2003-01-21 |
EP1296650B1 (de) | 2005-03-02 |
IL153656A0 (en) | 2003-07-06 |
ES2239144T3 (es) | 2005-09-16 |
DE60109164T2 (de) | 2005-12-29 |
WO2002000195A2 (en) | 2002-01-03 |
EP1296650A2 (de) | 2003-04-02 |
AU2001270177A1 (en) | 2002-01-08 |
JP2009001574A (ja) | 2009-01-08 |
JP2004501181A (ja) | 2004-01-15 |
CA2413545A1 (en) | 2002-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6509028B2 (en) | Methods and compositions for treating pain of the mucous membrane | |
US9814705B2 (en) | Intranasal spray device containing pharmaceutical composition | |
US8846641B2 (en) | Stabilized ophthalmic galactomannan formulations | |
HU199678B (en) | Process for producing aerosols containing nitroglicerol | |
US20080221144A1 (en) | Controlled Release Formulations | |
EP1559418A1 (de) | Zusammensetzungen zur Schmerzbehandlung der Schleimhaut | |
JP7359909B2 (ja) | 口腔用組成物の製造方法、口腔用組成物の口腔内塗布部との密着性を向上させる方法および口腔用組成物の口腔内塗布部における滞留性を向上させる方法。 | |
US7332528B2 (en) | DRI nasal sprays | |
JP4632687B2 (ja) | 点鼻剤 | |
JP7133981B2 (ja) | 外用組成物 | |
JP7125862B2 (ja) | 外用組成物 | |
JP2010280722A (ja) | 点鼻剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |